Sanara MedTech discontinues Tissue Health Plus business

Sanara MedTech (SMTI) announced that the company completed its previously announced evaluation of strategic alternatives for Tissue Health Plus. Following the completion of this evaluation, the company initiated a strategic realignment of its business, discontinuing operations of THP to improve its operating efficiency and reallocate resources to its core surgical business. As a result of the company’s strategic realignment, the operations of THP, which were previously reported as the THP segment, will be classified as discontinued operations in Sanara’s financial statements going forward in accordance with generally accepted accounting principles in the United States. The process of winding down THP is expected to continue through the end of 2025. The company continues to expect that the total cash investment in THP will range from $5.5M to $6.5M in the second half of 2025. The company does not expect to have material cash expenses related to THP after year-end.